Antibody Mediated Rejection clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for

  • BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)

    Sorry, in progress, not accepting new patients

    Primary Objectives: - Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR - Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: - To assess the overall efficacy of BIVV020 in prevention or treatment of AMR - To characterize the safety and tolerability of BIVV020 in kidney transplant participants - To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants - To evaluate the immunogenicity of BIVV020

    San Francisco, California and other locations

Last updated: